Book a meeting
DO-BO

Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)

In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71, which allows an early paid access.

Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.

In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.

Related

No Decisions for Us, Without Us: Why Patient Advocacy Matters in Market Access, Erica Bersin?

By

Stefan Walzer

In this episode of the Market Access Podcast, Erica Bersin – founder of ERO Health Communications – joins Dr. Stefan Walter to discuss the changing role of patient involvement in healthcare. Drawing on her experience in both Europe and the U.S., Erica explains how single-payer systems make patient engagement easier, while the U.S. faces more […]

Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günther Illert?

By

Stefan Walzer

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education. Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock […]

Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?

By

Stefan Walzer

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]